Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
As science and innovations continue to progress in gynaecological oncology, there is a need to rethink our perceptions to ensure clinical management and research advance accordingly
Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context
Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.